Table 2

Demographic characteristics of study subjects, stratified by allergy type

VariablesEnvironmental allergyFood allergyDrug allergy
N586238574
Age at last visit, mean (SD), years49.05 (11.56)48.52 (11.19)50.55 (11.72)
Age at first symptom, mean (SD), years33.39 (9.97)33.00 (9.87)33.56 (10.31)
Male, n (%)130 (22.18)37 (15.55)89 (15.51)
Disease duration at last visit, mean (SD), years15.66 (9.55)15.52 (9.16)17.06 (10.01)
Disease category, n (%)
 Primary progressive MS23 (3.92)11 (4.62)31 (5.40)
 Secondary progressive MS75 (12.80)31 (13.03)88 (15.33)
 Relapsing-remitting MS483 (82.42)191 (80.25)449 (78.22)
 Progressive relapsing MS5 (0.85)5 (2.10)6 (1.05)
Race, n (%)
 Asian4 (0.68)0 (0.00)2 (0.35)
 Black or African American24 (4.10)15 (6.30)26 (4.53)
 More than one race21 (3.58)9 (3.78)10 (1.74)
 Native Hawaiian/Pacific Islander1 (0.17)0 (0.00)1 (0.17)
 Unknown or not reported8 (1.37)2 (0.84)6 (1.05)
 White528 (90.10)210 (88.24)529 (92.16)
Ethnicity, n (%)
 Hispanic or Latino30 (5.12)13 (5.46)24 (4.18)
 Not Hispanic or Latino554 (94.54)224 (94.12)548 (95.47)
 Unknown or not reported2 (0.34)1 (0.42)2 (0.35)
% time on DMT, mean (SD)47.71 (29.57)45.14 (29.45)45.38 (29.35)
EDSS at last visit, median (IQR)2.0 (2.5)2.0 (2.5)2.0 (2.5)
MSSS at last visit, median (IQR)1.64 (3.04)1.83 (3.19)1.77 (2.96)
  • DMT, disease-modifyong therapy; EDSS, expanded disability status scale; MS, multiple sclerosis; MSSS, multiple sclerosis severity scale